Ernexa Therapeutics Inc. Sublease Income
Ernexa Therapeutics Inc. (ERNA) reported Sublease Income of $14.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SubleaseIncome · last filed 2026-08-06
- Ernexa Therapeutics Inc. sublease income for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Ernexa Therapeutics Inc. sublease income for the quarter ending 2026-03-31 was $14.00K, a 33.33% decline year-over-year.
- Ernexa Therapeutics Inc. sublease income for the quarter ending 2025-12-31 was $21.00K, a 0.00% change year-over-year.
- Ernexa Therapeutics Inc. sublease income for the quarter ending 2025-09-30 was $21.00K, a 0.00% change year-over-year.
- Ernexa Therapeutics Inc. sublease income for fiscal 2025 was $84.00K, a 0.00% change from fiscal 2024.
- Ernexa Therapeutics Inc. sublease income for fiscal 2024 was $84.00K, a 0.00% change from fiscal 2023.
- Ernexa Therapeutics Inc. sublease income for fiscal 2023 was $84.00K, a 0.00% change from fiscal 2022.
- Ernexa Therapeutics Inc. sublease income for fiscal 2022 was $84.00K, a 0.00% change from fiscal 2021.
| Period end | Sublease Income 3 month | Sublease Income 3 month as first filed | Sublease Income 6 month | Sublease Income 6 month as first filed | Sublease Income 9 month | Sublease Income 9 month as first filed | Sublease Income 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $14.00K 10-Q · filed 2026-08-06 | $35.00K derived: sum of 3 quarters · filed 2026-08-06 | $56.00K derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2026-03-31 | $14.00K 10-Q · filed 2026-05-11 | $35.00K derived: sum of 2 quarters · filed 2026-05-11 | $56.00K derived: sum of 3 quarters · filed 2026-05-11 | $77.00K derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-12-31 | $21.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $42.00K derived: sum of 2 quarters · filed 2026-03-13 | $63.00K derived: sum of 3 quarters · filed 2026-08-06 | $84.00K 10-K · filed 2026-03-13 | |||
| 2025-09-30 | $21.00K 10-Q · filed 2025-11-07 | $42.00K derived: sum of 2 quarters · filed 2026-08-06 | $63.00K 10-Q · filed 2025-11-07 | $84.00K derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-06-30 | $21.00K 10-Q · filed 2026-08-06 | $42.00K 10-Q · filed 2026-08-06 | $63.00K derived: sum of 3 quarters · filed 2026-08-06 | $84.00K derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-03-31 | $21.00K 10-Q · filed 2026-05-11 | $42.00K derived: sum of 2 quarters · filed 2026-05-11 | $63.00K derived: sum of 3 quarters · filed 2026-05-11 | $84.00K derived: sum of 4 quarters · filed 2026-05-11 | |||
| 2024-12-31 | $21.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $42.00K derived: sum of 2 quarters · filed 2026-03-13 | $63.00K derived: sum of 3 quarters · filed 2026-03-13 | $84.00K 10-K · filed 2026-03-13 | |||
| 2024-09-30 | $21.00K 10-Q · filed 2025-11-07 | $42.00K derived: sum of 2 quarters · filed 2025-11-07 | $63.00K 10-Q · filed 2025-11-07 | $84.00K derived: sum of 4 quarters · filed 2025-11-07 | |||
| 2024-06-30 | $21.00K 10-Q · filed 2025-08-13 | $42.00K 10-Q · filed 2025-08-13 | $63.00K derived: sum of 3 quarters · filed 2025-08-13 | $84.00K derived: sum of 4 quarters · filed 2025-08-13 | |||
| 2024-03-31 | $21.00K 10-Q · filed 2025-05-07 | $42.00K derived: sum of 2 quarters · filed 2025-05-07 | $63.00K derived: sum of 3 quarters · filed 2025-05-07 | $84.00K derived: sum of 4 quarters · filed 2025-05-07 | |||
| 2023-12-31 | $21.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $42.00K derived: sum of 2 quarters · filed 2025-03-12 | $63.00K derived: sum of 3 quarters · filed 2025-03-12 | $84.00K 10-K · filed 2025-03-12 | |||
| 2023-09-30 | $21.00K 10-Q · filed 2024-11-12 | $42.00K derived: sum of 2 quarters · filed 2024-11-12 | $63.00K 10-Q · filed 2024-11-12 | $84.00K derived: sum of 4 quarters · filed 2024-11-12 | |||
| 2023-06-30 | $21.00K 10-Q · filed 2024-08-13 | $42.00K 10-Q · filed 2024-08-13 | $63.00K derived: sum of 3 quarters · filed 2024-08-13 | $84.00K derived: sum of 4 quarters · filed 2024-08-13 | |||
| 2023-03-31 | $21.00K 10-Q · filed 2024-05-14 | $42.00K derived: sum of 2 quarters · filed 2024-05-14 | $63.00K derived: sum of 3 quarters · filed 2024-05-14 | $84.00K derived: sum of 4 quarters · filed 2024-05-14 | |||
| 2022-12-31 | $21.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $42.00K derived: sum of 2 quarters · filed 2024-03-14 | $63.00K derived: sum of 3 quarters · filed 2024-03-14 | $84.00K 10-K · filed 2024-03-14 | |||
| 2022-09-30 | $21.00K 10-Q · filed 2023-11-13 | $42.00K derived: sum of 2 quarters · filed 2023-11-13 | $63.00K 10-Q · filed 2023-11-13 | $85.00K derived: sum of 4 quarters · filed 2023-11-13 | |||
| 2022-06-30 | $21.00K 10-Q · filed 2023-08-11 | $42.00K 10-Q · filed 2023-08-11 | $64.00K derived: sum of 3 quarters · filed 2023-08-11 | $85.00K derived: sum of 4 quarters · filed 2023-08-11 | |||
| 2022-03-31 | $21.00K 10-Q · filed 2023-05-11 | $43.00K derived: sum of 2 quarters · filed 2023-05-11 | $64.00K derived: sum of 3 quarters · filed 2023-05-11 | $85.00K derived: sum of 4 quarters · filed 2023-05-11 | |||
| 2021-12-31 | $22.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $43.00K derived: sum of 2 quarters · filed 2023-03-20 | $64.00K derived: sum of 3 quarters · filed 2023-03-20 | $84.00K 10-K · filed 2023-03-20 | |||
| 2021-09-30 | $21.00K 10-Q · filed 2022-11-14 | $21.05K 10-Q · filed 2021-11-12 | $42.00K derived: sum of 2 quarters · filed 2022-11-14 | $62.00K 10-Q · filed 2022-11-14 | $62.12K 10-Q · filed 2021-11-12 | $77.88K derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | $21.00K 10-Q · filed 2022-08-11 | $21.05K 10-Q · filed 2021-08-13 | $42.00K 10-Q · filed 2022-08-11 | $42.09K 10-Q · filed 2021-08-13 | $56.88K derived: sum of 3 quarters · filed 2022-08-11 | $78.95K derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | $21.00K 10-Q · filed 2022-07-01 | $21.05K 10-Q · filed 2021-05-17 | $35.88K derived: sum of 2 quarters · filed 2022-07-01 | $57.95K derived: sum of 3 quarters · filed 2022-07-01 | $77.97K derived: sum of 4 quarters · filed 2022-07-01 | ||
| 2020-12-31 | $14.88K derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-07-01 | $36.95K derived: sum of 2 quarters · filed 2022-07-01 | $56.97K derived: sum of 3 quarters · filed 2022-07-01 | $77.00K 10-K/A · filed 2022-07-01 | |||
| 2020-09-30 | $22.06K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $42.09K derived: sum of 2 quarters · filed 2021-11-12 | $62.12K 10-Q · filed 2021-11-12 | ||||
| 2020-06-30 | $20.03K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $40.05K 10-Q · filed 2021-08-13 | |||||
| 2020-03-31 | $20.03K 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |